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INTRODUCTION 1
Brain-derived neurotrophic factor (BDNF) is broadly expressed in the central nervous system 2 (CNS) and plays crucial roles in neuronal maturation and survival, and synaptic functions 3 through intracellular signaling pathways including phosphoinositide 3-kinase/Akt (PI3K/Akt), 4 extracellular signal-regulated kinase (ERK), and phospholipase C-γ (PLC-γ) pathways [1] [2] [3] [4] . 5
Because transcription of the Bdnf gene is strictly regulated by environmental conditions, it has a 6 complex structure: at least nine 5' exons (exon I-IX) with a specific promoter and one 3' exon 7 (exon IX) encoding the entire open reading frame for BDNF protein in both humans and rodents 8 [5] [6] [7] . Transcription of Bdnf can be initiated at each of the 5' noncoding exons spliced to the 9 common 3' exon encoding the pre-proBDNF protein [7] . Extensive research has been devoted 10 to develop new medications for brain diseases under the strategy of improving the reduced 11 BDNF expression/function because BDNF has been suggested to be involved in the 12 pathogenesis of a variety of neurodegenerative and psychiatric diseases [8] [9] [10] [11] . 13 Dopamine plays important roles in the mammalian CNS, regulating motor actions and 14 cognitive functions such as learning, memory formation, decision making, and consummatory 15 behaviors controlled by the reward system through activating members of a G protein-coupled 16 receptor (GPCR) family [12, 13] . D1 to D5 dopamine receptors have been identified and 17 classified into two groups as D1-like (D1 and D5) and D2-like (D2, D3, and D4) receptors, 18 which promote activation or inhibition of adenylyl cyclase (AC), cyclic adenosine 19 monophosphate (cAMP) production, and protein kinase A (PKA), respectively [14, 15] . 20 Dopamine receptors are broadly distributed in the CNS: D1 and D2 receptors are the most 21 abundant two subtypes in the brain while D3, D4, and D5 expression is lower and more 22 regionally restricted. Despite extensive research into dopamine signaling in the CNS, actions of 23 dopamine remain elusive because they vary greatly by receptor subtypes, cell types, brain 24 regions, and strength and duration of stimulation [13, 16] . On the other hand, dopamine receptor 25 agonists have been clinically used in the treatment of Parkinson's disease patients [17] . 26
Rotigotine is a non-ergot agonist for dopamine receptors and has beneficial effects in the 27 treatment of Parkinson's disease [18] [19] [20] [21] [22] for dopamine D3 receptor (Ki 0.71 nM), a high affinity for D2, D4 and D5 receptors (Ki 4-15 31 nM), and a low affinity for D1 receptor (Ki 83 nM) by using an in vitro receptor binding assay 32 [26] . In functional studies, however, rotigotine was able to stimulate all dopamine receptor 33 experiment with haloperidol (3 rats as control and rotigotine group, respectively). 23
Rat primary cortical cultures and rotigotine treatment 24
Cortical neurons were prepared from the cortex of 1-or 2-day-old Wistar rats (SLC, Shizuoka, 25 Japan) as described previously [30] . Dissociated cells were plated at a final density of 26 5×10 5 /cm 2 on polyethyleneimine-coated culture dishes. Culture medium used in this study 27 contained 5% fetal bovine serum, 5% heated-inactivated horse serum, and 90% of a 1:1 mixture 28 of Dulbecco's modified Eagle's medium (DMEM) and Ham's F-12 medium. Cortical neurons 29
were matured for 10-11 days before rotigotine hydrochloride (Sigma-Aldrich) was treated, 30
followed by incubation for 6 or 24 hours before sampling. Corporation, Tokyo, Japan). At least 2 independent series of cultures were used for each set of 28 experiments. 29
Statistical analysis 30
Data are expressed as mean ± standard error (S.E.) and statistical significance was calculated 1 using Student's t-test or one-way ANOVA) followed by Bonferroni's post-hoc test by using 2 SPSS ver.18 (SPSS Japan, Tokyo, Japan). The probability values of less than 5% were 3 considered significant. 4
RESULTS 1

Subchronic rotigotine treatment increased BDNF protein levels in the rat cortex and 2 hippocampus 3
We first determined rotigotine's effect on BDNF and functionally related proteins in vivo. 4
Interestingly, BDNF protein levels were significantly increased in the cortex (1.55 ± 0.13, 5 normalized to the control, p=0.0018, Student's t-test) and hippocampus (1.31 ± 0.15, p=0.0081) 6 after 7 days of rotigotine administration ( Figure 1A , B). However, BDNF receptor TrkB, 7 glutamate receptor subunits, synaptic proteins, and phospho-ERK and -Akt levels were not 8 significantly changed by rotigotine in any of the three brain regions tested ( Figure 1A 
Rotigotine acutely reduced Bdnf mRNA expression in cultured cortical neurons 22
We then examined acute effects of rotigotine administration in cultured cortical neurons. 23
Rotigotine was administered to rat primary cortical neurons at 100 pM, 10 nM, and 1 M for 6 24 and 24 hours, and BDNF mRNA levels were measured using quantitative PCR with primer sets 25 for the exon I-, IV-, and IV-containing transcripts and for the common sequence shared by all 26
Bdnf mRNAs (total BDNF) ( Figure 3 ). We found that total Bdnf mRNA levels were acutely 27 reduced in cultured neurons by 6-hour rotigotine treatment at all doses ( Figure 3A) . The amount 28
of Bdnf transcripts derived from promoters for exon I and IV, which are strictly regulated by 29 neuronal activity, was also reduced by relatively low doses of rotigotine ( Figure 3B, 3C) . The 30 exon VI transcripts, whose transcription is not dependent on neural activity, also showed a 31 tendency towards reduction but there was no significant decrease at any dose tested ( Figure 3D ). 32
However, these rotigotine's effects were not apparent until 24 hours ( Figure 3E-H) . These data 1 suggest that rotigotine acutely reduced BDNF mRNA transcription in cortical neurons by 2 reducing neuronal network activity in cultured neurons. Rotigotine, however, did not affect 3 BDNF protein expression levels within 24 hours ( Figure 4A) . TrkB, N-methyl-d-aspartate 4 (NMDA) receptors (NR2A, B), and presynaptic proteins (SNAP25, synaptotagmin) levels were 5 also unchanged by the treatment ( Figure 4A, Supplementary Figure 4) . Although 6 phosphorylation levels of Akt were not clearly changed at any dose, phosphorylated ERK levels 7 were decreased at 6 hours in a dose-dependent manner and returned to the basal levels 24 hours 8 after treatment (Figure 4B, 4C) . To compare the proportion of dopamine receptor subtypes expressed in the three brain regions 12
and cortical cultures, dopamine receptor D1, D2, and D3 mRNA levels with or without 13 rotigotine treatment were determined. The D1 receptor was dominant in both the rat brain and 14 dissociated cultures while D2 and D3 receptors showed relatively high and limited expression 15 levels in the rat brain, respectively ( Figure 5A ). Relatively low levels of D2-like receptors were 16 expressed in cultured cortical neurons ( Figure 5B ), compared with those in rat brain regions. 17
Rotigotine treatment decreased D1 receptor mRNA in the cortex and increased in the 18 cerebellum of the rat brain while it had no effect in cortical cultures ( Figure 5A,B) . 19
DISCUSSION 1
In this study, we found that rotigotine increased BDNF protein levels in the rat cortex and 2 hippocampus. In the primary cortical culture, however, rotigotine acutely (at 6
high doses (500 nM <) decreased it via D2 receptor function in mouse acute prefrontal cortex 10 slices [32] . The proportions of D1/D2/D3 subtypes we revealed here were quite different 11 between the rat brain and dissociated cultures. D1 receptor was the dominant subtype both in 12 the rat brain and cultured cortical neurons whereas the D2 receptor was also substantially 13 expressed in the brain. Furthermore, haloperidol, which mainly antagonizes D2-like receptors, 14
showed a tendency to attenuate the rotigotine-induced up-regulation of BDNF. Therefore, it is 15 speculated that rotigotine increased BDNF protein levels through D2 receptor-dependent 16 modulation of neuronal activity although further electrophysiological recordings after rotigotine 17 treatment are needed. Another possible mechanism by which rotigotine increased BDNF protein only in the 19 rat brain is raised by the finding that protein levels, such as those of BDNF-related and synaptic 20 proteins and signaling molecule activation were unchanged even though BDNF expression was 21 increased. These results indicate that rotigotine could increase BDNF by a more direct 22 mechanism via dopamine receptor rather than via increasing neuronal activity. Recently an 23 important series of studies by George and colleagues have shown that the D1-D2 24 heterooligomers both in vitro and in vivo can mobilize intracellular Ca 2+ in response to 25 dopamine stimulation [33, 34] . They also revealed that dopamine induced BDNF production 26 through the D1-D2 heterooligomers, increasing intracellular Ca 2+ , phospholipase C (PLC), and 27 calcium/calmodulin-dependent kinase IICaMKII) activation [33, 34] . Because D2 receptor 28 levels were relatively high in the rat brain and very low in the cortical culture, the inconsistent 29 results showing that rotigotine increased BDNF levels only in the rat cortex/hippocampus, could 30 be attributed to the amount of the D1-D2 heterooligomer in each system [35, 36] . 31
Because the BDNF promoter I and IV are positively regulated by neuronal activity and 1 intracellular Ca 2+ concentration [7] , the reduction in the exon I and IV transcripts in cultured 2 neurons after the a 6-hour rotigotine treatment indicated a suppressive action on neuronal 3 activity and/or Ca 2+ influx both of which are mainly regulated by NMDA receptors. It was 4 reported that dopamine or SKF38393, a D1 receptor agonist, could directly block the NMDA 5 receptor and its currents in cultured neurons although the mechanisms underlying the 6 phenomena have not been fully clarified [37] [38] [39] . An acute and marked reduction of Bdnf 7 mRNA caused by rotigotine in dissociated neurons is very similar to the action of 8 phencyclidine, an NMDA receptor antagonist, observed in our previous studies [30] . Hence, 9 also considering that rotigotine clearly reduced ERK activity that is positively regulated by 10 NMDA receptor currents [40, 41] in cortical culture, rotigotine might have suppressed NMDA 11 currents in cultured neurons through a direct or indirect mechanism, which in turn caused the 12 reductions in the neuronal activity-dependent ERK activation and BDNF mRNA transcription. 13
Therefore, in a future study electrophysiological recordings of cultured neurons as well as in the 14 rat brain are important. 15
Our results revealed the discrepancy between BDNF mRNA and protein levels both in 16 the rat brains and cortical cultures. In the rat brain where BDNF protein levels were increased 17 and mRNA levels were unchanged after 7 days of rotigotine treatment, it is possible that BDNF 18 mRNA may be also up-regulated at early time points after the administration. antagonism by haloperidol on the rotigotine-induced BDNF up-regulation was not statistically 31 significant, action on 5-HT1A receptors may also be involved in the upregulation of BDNF 32 protein levels by rotigotine. The dopaminergic system has been increasingly receiving attentionas a target of treatment for brain diseases including psychiatric diseases [44, 45] . To return the 1 impaired system to a more normal condition, more information about receptor subtype 2 expression profiles and agonist properties is essential. Our study revealed a novel function of 3 rotigotine on BDNF expression although it also drew a challenge in basic research conducted 4 with in vivo and in vitro systems. Total Bdnf mRNA levels in the rat brain were determined by qPCR after rotigotine treatment.
Bdnf mRNA levels were normalized to Gapdh mRNA levels in each sample. All data represent mean ± S.E., (n=4-5). (n.s., not significant versus control., Student's t-test). Relative dopamine receptor D1, D2, and D3 mRNA levels were determined by qPCR in in vivo (A) and in vitro (B) rotigotine-treated samples. White, gray, and black bars indicate D1, D2, and D3 receptors, respectively. mRNA levels were normalized to GAPDH mRNA levels in each sample. All data represent mean ± S.E., (in vivo n=4-5, in vitro n=4 
